Literature DB >> 12413602

What is the recall rate of breast MRI when used for screening asymptomatic women at high risk?

Ruth M L Warren1, Linda Pointon, Rebecca Caines, Carmel Hayes, Deborah Thompson, Martin O Leach.   

Abstract

Breast screening acceptability is dependent on sensitivity and recall rate. We aimed to establish the recall rate for MRI and mammography, separately and together, when screening a cohort of women at high genetic risk. Women aged 35-49 years in the MARIBS study form the cohort. We analysed the recall rate, the number of extra tests and their effectiveness. Wilcoxon Rank test was used to estimate the effect of age and logistic regression with robust variance the effect of mammographic density on recall rates. The first 726 screening studies took place in 415 women. Following 86 of these recall occurred, comprising 140 additional investigations. 28 of the cases were resolved without further MRI, and 18 women had more than 2 additional tests. Neither age nor mammographic density was associated with recall. MRI had a recall of rate of 10.19%, and mammography 4.00%. The two techniques largely recalled different cases and 10 cases only (11.62% of those recalled) were abnormal by both tests. The two together had a recall rate of 11.85%. Recall rates varied widely between centres of the study. Breast MRI in asymptomatic high-risk women age 35-49 years largely recalls different women from mammography. The combined figure of approximately 12% may be acceptable for screening and will be useful for planning similar studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12413602     DOI: 10.1016/s0730-725x(02)00535-0

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  4 in total

1.  Breast MRI BI-RADS assessments and abnormal interpretation rates by clinical indication in US community practices.

Authors:  Christoph I Lee; Laura Ichikawa; Michele C Rochelle; Karla Kerlikowske; Diana L Miglioretti; Brian L Sprague; Wendy B DeMartini; Karen J Wernli; Bonnie N Joe; Bonnie C Yankaskas; Constance D Lehman
Journal:  Acad Radiol       Date:  2014-08-07       Impact factor: 3.173

2.  Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.

Authors:  Rodrigo Santa Cruz Guindalini; Yonglan Zheng; Hiroyuki Abe; Kristen Whitaker; Toshio F Yoshimatsu; Tom Walsh; David Schacht; Kirti Kulkarni; Deepa Sheth; Marion S Verp; Angela R Bradbury; Jane Churpek; Elias Obeid; Jeffrey Mueller; Galina Khramtsova; Fang Liu; Akila Raoul; Hongyuan Cao; Iris L Romero; Susan Hong; Robert Livingston; Nora Jaskowiak; Xiaoming Wang; Marcio Debiasi; Colin C Pritchard; Mary-Claire King; Gregory Karczmar; Gillian M Newstead; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Clin Cancer Res       Date:  2018-08-28       Impact factor: 12.531

Review 3.  Breast density implications and supplemental screening.

Authors:  Athina Vourtsis; Wendie A Berg
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

4.  Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.

Authors:  M Watson; C Foster; R Eeles; D Eccles; S Ashley; R Davidson; J Mackay; P J Morrison; P Hopwood; D G R Evans
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.